Kelleni MT. First use of nitazoxanide in Kelleni’s protocol for managing severe bronchiolitis in a 9-month-old infant: A case report and review of literature. World J Clin Cases 2025; 13(36): 113655 [DOI: 10.12998/wjcc.v13.i36.113655]
Corresponding Author of This Article
Mina Thabet Kelleni, MD, PhD, Assistant Professor, Department of Medical Pharmacology, College of Medicine, Minia University, Main Road Shalaby Land, Minya 61519, Egypt. mina.kelleni@mu.edu.eg
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 26, 2025 (publication date) through Dec 25, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Kelleni MT. First use of nitazoxanide in Kelleni’s protocol for managing severe bronchiolitis in a 9-month-old infant: A case report and review of literature. World J Clin Cases 2025; 13(36): 113655 [DOI: 10.12998/wjcc.v13.i36.113655]
World J Clin Cases. Dec 26, 2025; 13(36): 113655 Published online Dec 26, 2025. doi: 10.12998/wjcc.v13.i36.113655
First use of nitazoxanide in Kelleni’s protocol for managing severe bronchiolitis in a 9-month-old infant: A case report and review of literature
Mina Thabet Kelleni
Mina Thabet Kelleni, Department of Medical Pharmacology, College of Medicine, Minia University, Minya 61519, Egypt
Author contributions: Kelleni MT completed this manuscript all by himself.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report.
Conflict-of-interest statement: The author declares that he has no conflict of interest to disclose.
CARE Checklist (2016) statement: This case report adheres to the CARE guidelines to ensure complete and transparent reporting.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mina Thabet Kelleni, MD, PhD, Assistant Professor, Department of Medical Pharmacology, College of Medicine, Minia University, Main Road Shalaby Land, Minya 61519, Egypt. mina.kelleni@mu.edu.eg
Received: September 1, 2025 Revised: October 31, 2025 Accepted: December 15, 2025 Published online: December 26, 2025 Processing time: 116 Days and 17.2 Hours
Core Tip
Core Tip: This report presents the first documented use of nitazoxanide incorporated within Kelleni’s protocol to manage severe bronchiolitis in a 9-month-old infant. The infant presented with SpO2 84% on room air, tachypnea, and diffuse wheezing which was clinically consistent with severe viral bronchiolitis. Bronchiolitis is a leading cause of infant hospitalization and mortality worldwide, with limited effective antiviral treatments. Early administration of nitazoxanide, alongside other immunomodulatory therapies, showed clinical improvement as shown with resolution of fever and progressive improvement in in all symptoms, SpO2 rising from 84% to 92% and then 96% at full recovery in this severe case within two weeks. This approach highlights the potential to repurpose nitazoxanide and Kelleni’s protocol to safely manage severe lower viral respiratory tract infections in infants younger than one year.
